N@N

Matthew Harrison Maintained (VRTX) at Hold with Increased Target to $254 on, Apr 30th, 2021

Matthew Harrison of Morgan Stanley, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold with Increased Target from $253 to $254 on, Apr 30th, 2021.

Matthew has made no other calls on VRTX in the last 4 months.

There are 6 other peers that have a rating on VRTX. Out of the 6 peers that are also analyzing VRTX, 1 agrees with Matthew's Rating of Hold. Following is the relevant analyst calls for the last 4 months

---

• Geoffrey Porges of "SVB Leerink" Maintained at Hold with Decreased Target to $250 on, Tuesday, February 2nd, 2021

These are the ratings of the 5 analyists that currently disagree with Matthew

---

• Gena Wang of "Barclays" Maintained at Buy and Held Target at $302 on, Wednesday, April 21st, 2021
• Brian Skorney of "Baird" Maintained at Buy and Held Target at $252 on, Tuesday, April 20th, 2021
• Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $284 on, Tuesday, February 2nd, 2021
• Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $347 on, Tuesday, February 2nd, 2021
• Evan Seigerman of "Credit Suisse" Maintained at Buy with Decreased Target to $280 on, Tuesday, February 2nd, 2021

Contributing Sources

---